Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2010 by UPECLIN HC FM Botucatu Unesp.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Biophisics Department of Biosciences Institute - Unesp
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Information provided by:
UPECLIN HC FM Botucatu Unesp
ClinicalTrials.gov Identifier:
NCT01097811
First received: March 31, 2010
Last updated: April 27, 2010
Last verified: April 2010

March 31, 2010
April 27, 2010
June 2008
June 2010   (final data collection date for primary outcome measure)
Recovery of hepatic encephalopathy [ Time Frame: three years ] [ Designated as safety issue: No ]
comparison of efficacy between two drugs for the treatment of hepatic encephalopathy
Same as current
Complete list of historical versions of study NCT01097811 on ClinicalTrials.gov Archive Site
length of hospitalization caused by hepatic encephalopathy [ Time Frame: three years ] [ Designated as safety issue: No ]
comparison of efficacy between two drugs for reducing the length of hospitalization during treatment of hepatic encephalopathy
Same as current
Not Provided
Not Provided
 
Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy
Erythromycin Versus Neomycin Treatment for Overt Hepatic Encephalopathy: a Double-blind, Randomised, Controlled Trial.

Comparison between the efficacy of two different antibiotics in patients with overt hepatic encephalopathy. The study is randomized, controlled and double-blinded.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Hepatic Encephalopathy
  • Hypertension, Portal
  • Liver Cirrhosis
  • Drug: Erythromycin
    250 mg orally q.i.d.
  • Drug: Neomycin
    1 g orally q.i.d.
  • Active Comparator: Erythromycin
    Intervention: Drug: Erythromycin
  • Active Comparator: Neomycin
    Intervention: Drug: Neomycin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
20
December 2010
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Hepatic cirrhosis or portal hypertension
  • Hepatic Encephalopathy

Exclusion Criteria:

  • Acute liver failure
  • Neuropsychiatric diseases
  • Inflammatory bowel diseases
  • Intestinal obstruction
  • Shock
  • Renal insufficiency
  • Alcoholic hepatitis
  • Alcohol abuse
  • Antibiotic premedication
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Brazil
 
NCT01097811
upeclin/HC/FMB-Unesp-41
Yes
Fernando Gomes Romeiro / Doctor, Faculdade de Medicina de Botucatu - UNESP
UPECLIN HC FM Botucatu Unesp
  • Biophisics Department of Biosciences Institute - Unesp
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
Principal Investigator: Fernando G Romeiro Faculdade de Medicina de Botucatu - UNESP
Study Chair: Carlos A Caramori Faculdade de Medicina de Botucatu - UNESP
UPECLIN HC FM Botucatu Unesp
April 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP